UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point

One of Wall Street's large firms conscionable enactment its stamp of support connected a specialty pharma sanction that has been softly rallying. UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy with a $307 terms target, signaling the steadfast sees a constructive setup the marketplace hasn't yet priced. For semipermanent investors, the telephone lands astatine a infinitesimal erstwhile fundamentals, pipeline catalysts, and valuation look to beryllium converging.

Jazz Pharma banal has already tally hard into the upgrade, climbing 39% twelvemonth to day (YTD) and 116% implicit the past year. The UBS people sits good supra the existent statement of $241.76, suggesting the steadfast sees country for further repricing.

The Analyst's Case

The UBS upgrade apt centers connected a perceived inflection successful Jazz Pharmaceuticals' fundamentals. Oxybate franchise resilience, Epidiolex maturation successful epilepsy, oncology pipeline progression, and an charismatic valuation comparative to specialty pharma peers signifier the bull thesis.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Jazz Pharmaceuticals wasn't 1 of them. Get them present FREE.

Recent results backmost that view. Jazz Pharmaceuticals delivered $1.07 cardinal successful Q1 2026 revenue, a 19% twelvemonth implicit twelvemonth (YoY) gain, with adjusted EPS of $6.34 trouncing the $4.66 consensus. The oncology portfolio grew 45%, reinforcing the company's pivot narrative.

Company Snapshot

Jazz Pharmaceuticals is simply a biopharmaceutical institution focused connected neuroscience and oncology, with cardinal products including Xywav (sleep), Epidiolex (epilepsy), and Rylaze (oncology). The Dublin-based steadfast carries a marketplace capitalization of $14.4 billion.

Xywav, Jazz Pharma's pb slumber franchise, posted $408.2 cardinal successful Q1 sales, up 18%, portion Epidiolex contributed $249.8 million, up 15%. Zepzelca surged 60% to $101 cardinal connected its first-line tiny compartment lung crab combination.

Why the Move Matters Now

The terms people rise from UBS arrives up of a pivotal catalyst: the August 25 PDUFA day for zanidatamab successful first-line HER2-positive gastroesophageal cancer. Analysts task highest income imaginable of implicit $2 cardinal for the asset.